Reuters, like many other media outlets, covered Novo Nordisk’s request that the FDA add semaglutide...
Good coverage from Newsday
We’re pretty happy with Newsday’s coverage of how patients taking GLP-1 drugs will be affected by the shortages being over. Both APC Immediate Past Board Chair Joe Navarra and CEO Scott Brunner were quoted in the piece — Joe for perspective on how patients will likely be affected, and Scott about how compounders can make variations that aren't copies (and how that might be perceived).
